Lexaria Bioscience Corp

Lexaria Bioscience Corp. is a biotechnology company that offers DehydraTECH, a patented drug delivery-enabling platform. DehydraTECH combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds to improve bloodstream entry, increase effectiveness, allow lower overall dosing for improved tolerability, and promote healthier oral ingestion methods. The technology is used with a range of active molecules, including GLP-1 and GIP drugs, vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, nicotine and its analogs, and cannabinoids. It is applied to therapeutic indications such as diabetes, weight loss, hypertension, epilepsy, and heart disease, and is implemented in ingestible or topically administered formats including oral suspensions, tablets, capsules, foods, beverages, and oral products, suitable for pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. It was incorporated in 2004 and is headquartered in Kelowna, Canada.